Skip to main content
Equibles
ACRS logo

ACRS · Aclaris Therapeutics, Inc. · Analyst Estimates

Track ACRS — free

Use ACRS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ACRS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.90 +0.11 (+2.90%) Q1 2024 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$582.91M
Shares
147.20M
Volume · Oct 28 3.88M Avg daily vol (3M) 2.85M

Analyst Estimates

Compare analyst forecasts for Aclaris Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-28 09:22 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.74
-0.64
-0.54
11
-0.65
-0.64
-0.65
-0.66
3
3
4
4
Revenue
USD
Publication date not stated
3.60M
6.18M
7.88M
11
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.21
-0.75
-0.40
11
-0.78
-0.79
-0.81
-0.83
4
4
4
4
Revenue
USD
Publication date not stated
0.00
5.34M
10.90M
11
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.18
-0.16
-0.14
11
-0.16
-0.17
-0.17
-0.17
1
1
4
4
Revenue
USD
Publication date not stated
0.00
1.23M
2.05M
11
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-0.25
-0.18
-0.13
11
-0.18
-0.17
-0.18
-0.17
3
3
4
4
Revenue
USD
Publication date not stated
0.00
1.35M
2.70M
11
 — — — — — — — —
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 26 filings 21 filers Visit website Investor relations